Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034443 | 0.82 | GABRA1 (0.39) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL2030683 | 0.77 | KMT2A (0.41) | KMT2AKDM4ENPC1RAB9ACYP1A2 | |
| SCHEMBL13813433 | 0.76 | POLB (0.39) | KMT2AKDM4ENPC1RAB9ACYP1A2 | |
| SCHEMBL4032310 | 0.74 | PKM (0.40) | KMT2AKDM4ENPC1RAB9ACYP1A2 | |
| SCHEMBL22424328 | 0.74 | KDM4E (0.44) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| Hydrochloric Acid SCHEMBL7170504 | 0.73 | KDM4E (0.43) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL13130413 | 0.72 | CYP1A2 (0.43) | GABRA1GABRA2GABRB2KMT2AKDM4E | |
| SCHEMBL29957431 | 0.72 | TSHR (0.40) | KMT2AKDM4ENPC1RAB9ACYP1A2 | |
| SCHEMBL2928318 | 0.71 | CYP3A4 (0.50) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL16620848 | 0.70 | KDM4E (0.43) | GABRA1GABRA5GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278307-B2 | Monocyclic Heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| EP-1725544-B1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1725544-B1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7514458-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514458-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1887003-A1 | 3-[4-HETEROCYCLYL -1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | GABRA1 1011/4885GABRA5 596/4885GABRG2 709/4885 |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | TNF, IL6, IL1A | GABRA1 3021/4885GABRA5 2963/4885GABRG2 2803/4885 |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL1A | GABRA1 3021/4885GABRA5 2963/4885GABRG2 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.